References
- Carreno JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022 Feb;602(7898):682–688. doi:10.1038/s41586-022-04399-5
- Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023 Jan 19;186(2):279–286.e8. doi:10.1016/j.cell.2022.12.018
- Tan CW, Zhu F, Chia WN, et al. Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals. hLife. 2023 Nov 1;1(1):26–34. doi:10.1016/j.hlife.2023.07.002
- He Y, Lu H, Siddiqui P, et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005 Apr 15;174(8):4908–4915. doi:10.4049/jimmunol.174.8.4908
- He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004 Nov 12;324(2):773–781. doi:10.1016/j.bbrc.2004.09.106
- Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009 Mar;7(3):226–236. doi:10.1038/nrmicro2090
- Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020 Aug 6;182(3):722–733.e11. doi:10.1016/j.cell.2020.06.035
- Hu S, Wu C, Wu X, et al. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities. Sci Bull (Beijing). 2023 Dec 15;68(23):3003–3012. doi:10.1016/j.scib.2023.09.048
- Tan TK, Rijal P, Rahikainen R, et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun. 2021 Jan 22;12(1):542. doi:10.1038/s41467-020-20654-7
- Zhao X, Li D, Ruan W, et al. Effects of a prolonged booster interval on neutralization of Omicron variant. N Engl J Med. 2022 Mar 3;386(9):894–896. doi:10.1056/NEJMc2119426
- Liu Z, Zhou J, Xu W, et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022 Mar;32(3):269–287. doi:10.1038/s41422-022-00612-2
- Liu Z, Zhou J, Wang X, et al. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates. Proc Natl Acad Sci U S A. 2023 Mar 14;120(11):e2221713120. doi:10.1073/pnas.2221713120
- Liu Z, Xu W, Chen Z, et al. An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. Protein Cell. 2022 Sep;13(9):655–675. doi:10.1007/s13238-021-00871-6
- Qu X, Jia Y, Jia N, et al. Mouse model for pangolin-origin coronavirus GX/P2 V/2017 infection and cross-protection from COVID-19 ZF2001 subunit vaccine. hLife. 2023 Nov 1;1(1):35–43. doi:10.1016/j.hlife.2023.07.001
- Wang X, Sun L, Liu Z, et al. An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen. Emerg Microbes Infect. 2023 Dec;12(2):2244084. doi:10.1080/22221751.2023.2244084